News
![Formulaire de déclaration mensuelle des droits de vote - Janvier 2014](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Formulaire de déclaration mensuelle des droits de vote - Janvier 2014
Le 11 février 2014
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
![Activité 2013](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Activité 2013
ACTIVITÉ 2013
(Données non auditées)
ACTIVITÉ CUMULÉE À FIN DÉCEMBRE 2013
en milliers d'euros
2012
2013
Var. taux courant 2013/2012
Var. taux constant....
![Activity in 2013](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Activity in 2013
ACTIVITY IN 2013
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2013
thousands of euros
2012
2013
Variation at current exchange rates
Variation at constant....
![EnWave unterzeichnet Verlängerung mit Gay Lea Foods Cooperative Ltd.](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
EnWave unterzeichnet Verlängerung mit Gay Lea Foods Cooperative Ltd.
EnWave Corporation gab heute bekannt, dass man eine Verlängerung mit Gay Lea Foods Cooperative Ltd. unterzeichnet hat. Dies erlaubt es Gay Lea Foods für weitere 6 Monate mit der Radiant Energy
![Bilan semestriel du contrat de liquidité BOIRON au 31 décembre 2013](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Bilan semestriel du contrat de liquidité BOIRON au 31 décembre 2013
Le 14 Janvier 2014
Bilan semestriel du contrat de liquidité BOIRON
contracté avec NATIXIS
Au titre du contrat de liquidité confié à NATIXIS portant sur les actions de la société BOIRON, à....
![Modification of the schedule of the 2014 publications](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Modification of the schedule of the 2014 publications
The publication of the 2013 annual sales revenue, initially scheduled on January 23, 2014, will be made on January 24, 2014 at market close.
The publication of the 2014 first quarter sales....
![Modification du calendrier des publications 2014](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Modification du calendrier des publications 2014
La publication du chiffre d'affaires annuel 2013, initialement prévue le jeudi 23 janvier 2014, aura lieu le vendredi 24 janvier 2014, après bourse.
La publication du chiffre d'affaires du....
![Formulaire de déclaration mensuelle des droits de vote - Décembre 2013](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Formulaire de déclaration mensuelle des droits de vote - Décembre 2013
Le 14 janvier 2014
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
![Formulaire de déclaration mensuelle des droits de vote - Novembre 2013](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Formulaire de déclaration mensuelle des droits de vote - Novembre 2013
Le 5 décembre 2013
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
![Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer,....
![Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments
Working Closely With Collaboration Partner GSK to Analyze Benefit-to-Risk Profile of drisapersen Across All Studies
LEIDEN, The Netherlands, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding....
![haussier stallergènes](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
haussier stallergènes
Stallergènes près pour un évasion
![haussier](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
haussier
poursuit sa hausse
![New England Journal of Medicine Publishes Positive Data From Clinical Trial of Novavax' Vaccine Against H7N9 Avian Flu](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
New England Journal of Medicine Publishes Positive Data From Clinical Trial of Novavax' Vaccine Against H7N9 Avian Flu
Data are industry's first from clinical trial of vaccine against A(H7N9) strain of influenza
81% of 5ug adjuvanted vaccine recipients had protective HAI levels
97% of 5ug adjuvanted....
![Formulaire de déclaration mensuelle des droits de vote - Octobre 2013](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Formulaire de déclaration mensuelle des droits de vote - Octobre 2013
Le 12 novembre 2013
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
![Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis
Data to Date Support Results From Long-Term Phase 3 Study
NEW YORK, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced preliminary, unaudited data....
![Novavax Reports Third-Quarter 2013 Financial Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Novavax Reports Third-Quarter 2013 Financial Results
ROCKVILLE, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of....
![Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus...](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus...
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney....
![Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus...](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus...
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney....
![Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013
ROCKVILLE, Md., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial....
![ACTIVITY IN THE THIRD QUARTER OF 2013](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ACTIVITY IN THE THIRD QUARTER OF 2013
ACTIVITY IN THE THIRD QUARTER OF 2013
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2013
thousands of euros
2012
2013
Variation at current exchange....
![ACTIVITE DU TROISIEME TRIMESTRE 2013](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
ACTIVITE DU TROISIEME TRIMESTRE 2013
ACTIVITE DU TROISIEME TRIMESTRE 2013
(Données non auditées)
ACTIVITE CUMULEE A FIN SEPTEMBRE 2013
en milliers d'euros
2012
2013
Var. taux courant 2013/2012
Var. taux constant....
![Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
Study Conducted by Development Partner R-Tech Ueno and Majority-Funded by Japan Science and Technology Agency (JST)
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary....
![Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug Application](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug Application
NEW YORK, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee....
![EnWave startet Moon Cheese® durch NutraDried LLP](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EnWave startet Moon Cheese® durch NutraDried LLP
Die EnWave Corporation gab am 17 Oktober 2013 bekannt, dass NutraDried LLP eine Partnerschaft mit Lucid Capital Management begonnen hat, die offiziell mit dem Start von Moon Cheese®, die durch EnWave´s